Core Viewpoint - Livzon Pharmaceutical Group Inc. has announced that its subsidiary, Zhuhai Livzon Monoclonal Antibody Biotechnology Co., Ltd., in collaboration with Beijing Xinkanghe Biological Pharmaceutical Technology Co., Ltd., has had its product, Lakanqita Monoclonal Antibody Injection, included in the priority review list by the National Medical Products Administration of China, marking a significant step towards expedited approval for market entry [1] Group 1 - The product Lakanqita Monoclonal Antibody Injection was officially included in the priority review list after the public announcement period ended [1] - The inclusion in the priority review list indicates that the product will undergo expedited approval procedures for drug market licensing [1]